维昇药业于2018年11月成立，是一家处于研发后期、产品接近商业化的生物制药公司，专注于在中国提供特定内分泌疾病的治疗方案。公司拥有一款核心产品及两款其他在研候选药物，该等候选药物均自公司的合作伙伴及控股股东之一Ascendis Pharma授权引入。
Futu News reported on March 20, $VISEN PHARMA-B (02561.HK)$ Today, the dark market opened lower, currently down 15.92%, reported at 57.85 Hong Kong dollars, with a transaction volume of 3.4424 million Hong Kong dollars and a total market value of 6.505 billion Hong Kong dollars.
Market data source: Futu Securities
Company Overview
Weisheng Pharmaceuticals was established in November 2018. It is a biopharmaceutical company in the late stages of research and development, focusing on providing treatment solutions for specific endocrine diseases in China. The company has one core product and two other candidate drugs under research, which have been licensed from one of its partners and major shareholders, Ascendis Pharma.
The company's core product, Longpei growth hormone, is a candidate drug researched by the company, which has completed phase 3 key trials in China for the treatment of growth hormone deficiency in children aged 3 to 17, with each subject receiving 52 weeks of treatment. The completed phase 3 key trials in China have verified that Longpei growth hormone is the only LAGH that has demonstrated superior efficacy and comparable safety in comparison to positive controls of short-acting (daily injection) human growth hormone and parallel group trials.
Financial Overview
In terms of financial status, Weisheng Pharmaceutical-B currently does not have products approved for commercial sale and has not generated any revenue from product sales. Since its establishment, the company has incurred operating losses in each fiscal year and during the historical record period. For the nine months ended September 30, 2024, the company's research and development costs were RMB 0.18 billion, RMB 57.69 million, and RMB 58.907 million for 2022, 2023, and the nine months ending September 30, 2024, respectively.
Futu draws new stocks, truly 0 interest* | 0 handling fees^, dark market trade one step ahead,Come and experience it >>
Become a Futubull member and enjoy the advantage of new stock allocations >>
For details, please click:Three major rights of members to subscribe for new stocks! Keep it all in one article!
Editor/Joe
Today, after hitting the high near 24,000 in the early session and entering bearish positions, the index fell sharply by nearly over 600 points, immediately recouping yesterday's losses significantly.
Moreover, today it broke the new high again, reaching a maximum of 24,076, but by the end of the market, it fell back by about 70 points, producing a bearish candle. The current trend has not yet been broken, but from the previous low until now, it has risen close to 6,000 points. It is believed that those with positions can continue to hold until there is a clear trend reversal for profit-taking. Those without positions can wait for a pullback to get in. Actually, it is hoped for a quick pullback, as it allows for entry and also provides a healthy breath.
Currently, the outlook remains the same as before. It is believed that even if there is a pullback, it shouldn't be too deep. However, if Futures fail to stabilize and close below 22,350, there may still be room for decline. The chance of Futures falling below 21,400 in the short term should be low, so it is considered that if a significant pullback occurs, it presents a good opportunity to incrementally go long. Recently, there has been a consistent approach to not hold positions overnight, only focusing on immediate trades, as there is no high chasing and no casual short selling.
Comment(1)
Reason For Report